Results 331 to 340 of about 436,330 (367)
Some of the next articles are maybe not open access.
Safety of Janus Kinase Inhibitors: A Real-World Multicenter Retrospective Cohort Study
Journal of Rheumatology, 2023Objective Oral Janus kinase inhibitors (JAKis) represent an effective strategy for rheumatoid arthritis (RA) treatment. A previous study supported that tofacitinib (TOF) is associated with higher incidence of cardiovascular (CV) and neoplastic events ...
M. Lanzillotta +11 more
semanticscholar +1 more source
British Journal of Dermatology, 2023
BACKGROUND On the basis of safety data on patients with inflammatory rheumatism or inflammatory bowel disease, treatment with Janus kinase (JAK) inhibitors has been linked to the occurrence of major adverse cardiovascular events (MACEs).
Cécile Ertus +7 more
semanticscholar +1 more source
BACKGROUND On the basis of safety data on patients with inflammatory rheumatism or inflammatory bowel disease, treatment with Janus kinase (JAK) inhibitors has been linked to the occurrence of major adverse cardiovascular events (MACEs).
Cécile Ertus +7 more
semanticscholar +1 more source
Investigational Janus kinase inhibitors
Expert Opinion on Investigational Drugs, 2013Dysregulation of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway is central to the pathophysiology of myeloproliferative neoplasms (MPN). Small molecule inhibitors of JAK family members are currently under investigation for the treatment of MPN.
Constantine S, Tam, Srdan, Verstovsek
openaire +2 more sources
Emerging role of topical Janus Kinase inhibitors in dermatological disorders.
Clincal and Experimental Dermatology, 2023JAK refers to a family of tyrosine kinases that are involved in production of pro-inflammatory mediators in response to various extracellular signals.
S. Dogra +3 more
semanticscholar +1 more source
Oral Janus kinase inhibitors for atopic dermatitis
Annals of Allergy, Asthma & Immunology, 2023Atopic dermatitis (AD) is one of the most common inflammatory skin conditions. The pathogenesis of AD involves skin barrier disruption and immune activation of T-helper (TH)2 and TH22 and varying degrees of TH1 and TH17 activation in various patient subtypes.
Daniela, Mikhaylov +3 more
openaire +2 more sources
Novel Janus-kinase (JAK) Inhibitors in Myelofibrosis
Expert Opinion on Investigational Drugs, 2023JAK inhibitors (JAKis), used in the treatment of myelofibrosis, have entered standard treatment, providing significant improvements in spleen size and symptom burden. Although splenomegaly provides a reduction and some improvement in cytopenia, there is still a way to go. Novel JAKis are being investigated to overcome barriers to treatment access, such
Yildiz Ipek +3 more
openaire +2 more sources
Janus kinase inhibitors for treatment of morphea and systemic sclerosis: A literature review
Dermatologic Therapy, 2022Morphea and systemic sclerosis (SSc) are rare disorders of connective tissue characterized by increased skin thickness and fibrosis, with current treatment options having variable efficacies, many with limited therapeutic benefit.
S. McGaugh +3 more
semanticscholar +1 more source
2017
To control gene expression, cytokines and other extracellular molecules utilize the Janus kinase (JAK) and signal transducers and activators of transcription (STAT). Dysregulation of the JAK-STAT pathway has been implicated in a myriad of inflammatory and hematologic disorders.
Andrew Kim, Bruce Strober
openaire +1 more source
To control gene expression, cytokines and other extracellular molecules utilize the Janus kinase (JAK) and signal transducers and activators of transcription (STAT). Dysregulation of the JAK-STAT pathway has been implicated in a myriad of inflammatory and hematologic disorders.
Andrew Kim, Bruce Strober
openaire +1 more source
[Pharmacology of Janus kinase inhibitors].
Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete, 2019Modern dermatotherapy is dominated by the development of various biologicals and small molecules. Janus kinase inhibitors (JAKi) form a novel class of small molecular synthetic compounds inhibiting the intracellular signal transduction of cytokine receptors. Cytokines are key mediators in the pathophysiology of numerous inflammatory skin diseases. Many
F, Solimani, F J, Hilke, K, Ghoreschi
openaire +2 more sources
Phenylaminopyrimidines as inhibitors of Janus kinases (JAKs)
Bioorganic & Medicinal Chemistry Letters, 2009A series of phenylaminopyrimidines has been identified as inhibitors of Janus kinases (JAKs). Development of this initial series led to the potent JAK2/JAK1 inhibitor CYT387 (N-(cyanomethyl)-4-[2-[[4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]-benzamide). Details of synthesis and SAR studies of these compounds are reported.
Burns, Christopher J. +22 more
openaire +3 more sources